Nutra Pharma Announces Upcoming Webinar to Discuss the Company’s Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain

Share Article

Nutra Pharma will be conducting a webinar on December 10, 2009, to discuss the Company’s over-the-counter and prescription treatments for chronic pain, Cobroxin and Nyloxin Rx.

Nutra Pharma Corporation

We would like to invite all of our shareholders and other interested parties to join us on this webinar so that we may explain our current progress and our short-term and long-term goals.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be hosting an online webinar on December 10, 2009, at 9PM ET to discuss current progress with Cobroxin and Nyloxin Rx, the Company’s treatments for chronic pain.

“Over the past few months, we have been gaining traction in the pain market through the launch of our over-the-counter pain reliever, Cobroxin, and our recently introduced prescription pain reliever, Nyloxin Rx,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We would like to invite all of our shareholders and other interested parties to join us on this webinar so that we may explain our current progress and our short-term and long-term goals,” he added.

Registration is limited. To register for the upcoming webinar, visit http://tinyurl.com/NPHCwebinar.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
http://www.Nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the upcoming webinar about the Company’s treatments for chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at http://www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact:
Nutra Pharma Corp.
David Isserman
877-895-5647

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Isserman
Visit website